

Arthur M Krieg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11141205/publications.pdf>

Version: 2024-02-01

195
papers

26,690
citations

7087

78
h-index

5820

161
g-index

201
all docs

201
docs citations

201
times ranked

16378
citing authors

#	ARTICLE	IF	CITATIONS
1	Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma. <i>Cancer Discovery</i> , 2021, 11, 2998-3007.	7.7	80
2	Antibody Opsonization of a TLR9 Agonist-Containing Virus-like Particle Enhances In Situ Immunization. <i>Journal of Immunology</i> , 2020, 204, 1386-1394.	0.4	37
3	Rigging Innate Immunity against the Flu. <i>Molecular Therapy</i> , 2017, 25, 1993-1994.	3.7	0
4	The ability of CpG oligonucleotides to protect mice against <i>Francisella tularensis</i> live vaccine strain but not fully virulent <i>F.Âtularensis</i> subspecies <i>holarctica</i> is reflected in cell-based assays. <i>Microbial Pathogenesis</i> , 2013, 63, 16-18.	1.3	4
5	Clinical Evaluation of Safety and Immunogenicity of PADRE-Cytomegalovirus (CMV) and Tetanus-CMV Fusion Peptide Vaccines With or Without PF03512676 Adjuvant. <i>Journal of Infectious Diseases</i> , 2012, 205, 1294-1304.	1.9	86
6	CpG Still Rocks! Update on an Accidental Drug. <i>Nucleic Acid Therapeutics</i> , 2012, 22, 77-89.	2.0	171
7	Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E797-803.	3.3	88
8	Immunostimulatory Potential of Silencing RNAs Can Be Mediated by a Non-Uridine-Rich Toll-Like Receptor 7 Motif. <i>Nucleic Acid Therapeutics</i> , 2011, 21, 201-214.	2.0	21
9	Positive T cell co-stimulation by TLR7/8 ligands is dependent on the cellular environment. <i>Immunobiology</i> , 2011, 216, 12-23.	0.8	15
10	Combining Vaccination and Postexposure CpG Therapy Provides Optimal Protection Against Lethal Sepsis in a Biodefense Model of Human Melioidosis. <i>Journal of Infectious Diseases</i> , 2011, 204, 636-644.	1.9	24
11	Subcutaneous, but not intratracheal administration of the TLR9 agonist, CpG DNA transiently reduces parainfluenza-3 virus shedding in newborn lambs. <i>Comparative Immunology, Microbiology and Infectious Diseases</i> , 2010, 33, e111-e117.	0.7	7
12	AIMing 2 defend against intracellular pathogens. <i>Nature Immunology</i> , 2010, 11, 367-369.	7.0	19
13	A Novel Class of Immune-Stimulatory CpG Oligodeoxynucleotides Unifies High Potency in Type I Interferon Induction with Preferred Structural Properties. <i>Oligonucleotides</i> , 2010, 20, 93-101.	2.7	67
14	Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy. <i>Progress in Respiratory Research</i> , 2010, , 95-99.	0.1	2
15	Early development of the Toll-like receptor 9 agonist, PF-3512676, for the treatment of patients with advanced cancers. <i>Expert Opinion on Drug Discovery</i> , 2009, 4, 587-603.	2.5	6
16	AIMing 2 Detect Foreign DNA. <i>Science Signaling</i> , 2009, 2, pe39.	1.6	8
17	Sequences derived from self-RNA containing certain natural modifications act as suppressors of RNA-mediated inflammatory immune responses. <i>International Immunology</i> , 2009, 21, 607-619.	1.8	37
18	Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 615-628.	2.0	100

#	ARTICLE	IF	CITATIONS
19	NK cells activated in vivo by bacterial DNA control the intracellular growth of <i>Francisella tularensis</i> LVS. <i>Microbes and Infection</i> , 2009, 11, 49-56.	1.0	20
20	Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. <i>Advanced Drug Delivery Reviews</i> , 2009, 61, 195-204.	6.6	500
21	CpG oligodeoxynucleotides augment the murine immune response to the <i>Yersinia pestis</i> F1-V vaccine in bubonic and pneumonic models of plague. <i>Vaccine</i> , 2009, 27, 2220-2229.	1.7	30
22	Immunostimulatory effects of three classes of CpG oligodeoxynucleotides on PBMC from HCV chronic carriers. <i>Journal of Immune Based Therapies and Vaccines</i> , 2008, 6, 3.	2.4	19
23	A combination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits NALT dendritic cells for prolonged mucosal immunity. <i>Vaccine</i> , 2008, 26, 4849-4859.	1.7	61
24	Attenuated cytokine responses in porcine lymph node cells stimulated with CpG DNA are associated with low frequency of IFN γ -producing cells and TLR9 mRNA expression. <i>Veterinary Immunology and Immunopathology</i> , 2008, 123, 324-336.	0.5	15
25	CD14+ cells are required for IL-12 response in bovine blood mononuclear cells activated with Toll-like receptor (TLR) 7 and TLR8 ligands. <i>Veterinary Immunology and Immunopathology</i> , 2008, 126, 273-282.	0.5	14
26	Identification of RNA Sequence Motifs Stimulating Sequence-Specific TLR8-Dependent Immune Responses. <i>Journal of Immunology</i> , 2008, 180, 3729-3738.	0.4	264
27	The Toll of Cathepsin K Deficiency. <i>Science</i> , 2008, 319, 576-577.	6.0	17
28	Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 3979-3986.	0.8	157
29	Toll-Like Receptor 9 Regulates the Lung Macrophage Phenotype and Host Immunity in Murine Pneumonia Caused by <i>Legionella pneumophila</i> . <i>Infection and Immunity</i> , 2008, 76, 2895-2904.	1.0	71
30	Activation of Innate Immunity in Healthy <i>Macaca mulatta</i> Macaques by a Single Subcutaneous Dose of GMP CpG 7909: Safety Data and Interferon-Inducible Protein-10 Kinetics for Humans and Macaques. <i>Vaccine Journal</i> , 2008, 15, 221-226.	3.2	17
31	TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. <i>Blood</i> , 2008, 112, 3508-3516.	0.6	75
32	TLR9 Is Required for Protective Innate Immunity in Gram-Negative Bacterial Pneumonia: Role of Dendritic Cells. <i>Journal of Immunology</i> , 2007, 179, 3937-3946.	0.4	102
33	Antiinfective Applications of Toll-like Receptor 9 Agonists. <i>Proceedings of the American Thoracic Society</i> , 2007, 4, 289-294.	3.5	93
34	Lymphoma Immunotherapy with CpG Oligodeoxynucleotides Requires TLR9 Either in the Host or in the Tumor Itself. <i>Journal of Immunology</i> , 2007, 179, 2493-2500.	0.4	119
35	Innate immune responses induced by classes of CpG oligodeoxynucleotides in ovine lymph node and blood mononuclear cells. <i>Veterinary Immunology and Immunopathology</i> , 2007, 115, 24-34.	0.5	30
36	Systemic innate immune responses following intrapulmonary delivery of CpG oligodeoxynucleotides in sheep. <i>Veterinary Immunology and Immunopathology</i> , 2007, 115, 357-368.	0.5	10

#	ARTICLE	IF	CITATIONS
37	The Toll of Too Much TLR7. <i>Immunity</i> , 2007, 27, 695-697.	6.6	33
38	Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non-Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2007, 13, 6168-6174.	3.2	111
39	PD3-1-6: PF-3512676 (CPG 7909), a toll-like receptor 9 agonist-status of development for non-small cell lung cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2007, 2, S461.	0.5	6
40	Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine. <i>International Journal of Cancer</i> , 2007, 121, 1520-1528.	2.3	45
41	TLR9 and DNA 'feel' RAGE. <i>Nature Immunology</i> , 2007, 8, 475-477.	7.0	18
42	Toll-free vaccines?. <i>Nature Biotechnology</i> , 2007, 25, 303-305.	9.4	30
43	Impact of class A, B and C CpG-oligodeoxynucleotides on in vitro activation of innate immune cells in human immunodeficiency virus-1 infected individuals. <i>Immunology</i> , 2007, 120, 526-535.	2.0	52
44	Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. <i>Immunological Reviews</i> , 2007, 220, 251-269.	2.8	313
45	Dendritic cells from HIV-1 infected individuals are less responsive to toll-like receptor (TLR) ligands. <i>Cellular Immunology</i> , 2007, 250, 75-84.	1.4	74
46	Development of TLR9 agonists for cancer therapy. <i>Journal of Clinical Investigation</i> , 2007, 117, 1184-1194.	3.9	369
47	Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist. <i>Antiviral Therapy</i> , 2007, 12, 741-51.	0.6	18
48	Safety, Pharmacokinetics and Immune Effects in Normal Volunteers of CPG 10101 (ACTILON), an Investigational Synthetic Toll-like Receptor 9 Agonist. <i>Antiviral Therapy</i> , 2007, 12, 741-751.	0.6	40
49	Phase II Trial of a Toll-Like Receptor 9 Activating Oligonucleotide in Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 5716-5724.	0.8	197
50	Surgical excision combined with autologous whole tumor cell vaccination is an effective therapy for murine neuroblastoma. <i>Journal of Pediatric Surgery</i> , 2006, 41, 1361-1368.	0.8	26
51	Potential use of CpG ODN for cancer immunotherapy. <i>Update on Cancer Therapeutics</i> , 2006, 1, 49-58.	0.9	3
52	Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer. <i>Vaccine</i> , 2006, 24, 6155-6162.	1.7	27
53	Oligodeoxynucleotide CpG 7909 Delivered as Intravenous Infusion Demonstrates Immunologic Modulation in Patients With Previously Treated Non-Hodgkin Lymphoma. <i>Journal of Immunotherapy</i> , 2006, 29, 558-568.	1.2	145
54	Therapeutic potential of Toll-like receptor 9 activation. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 471-484.	21.5	1,115

#	ARTICLE	IF	CITATIONS
55	CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 515-527.	2.0	28
56	Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses. <i>Experimental Hematology</i> , 2006, 34, 1403-1412.	0.2	24
57	Modulating responsiveness of human TLR7 and 8 to small molecule ligands with T-rich phosphorothiate oligodeoxynucleotides. <i>European Journal of Immunology</i> , 2006, 36, 1815-1826.	1.6	83
58	Structure-Activity Relationship Studies on the Immune Stimulatory Effects of Base-Modified CpG Toll-Like Receptor 9 Agonists. <i>ChemMedChem</i> , 2006, 1, 1007-1014.	1.6	32
59	High Mobility Group B1 Protein Suppresses the Human Plasmacytoid Dendritic Cell Response to TLR9 Agonists. <i>Journal of Immunology</i> , 2006, 177, 8701-8707.	0.4	59
60	Activation of Plasmacytoid Dendritic Cells with TLR9 Agonists Initiates Invariant NKT Cell-Mediated Cross-Talk with Myeloid Dendritic Cells. <i>Journal of Immunology</i> , 2006, 177, 1028-1039.	0.4	66
61	Stimulation of Innate Immune Responses by CpG Oligodeoxynucleotide in Newborn Lambs Can Reduce Bovine Herpesvirus-1 Shedding. <i>Oligonucleotides</i> , 2006, 16, 58-67.	2.7	26
62	A CpG Oligonucleotide Can Protect Mice from a Low Aerosol Challenge Dose of <i>Burkholderia mallei</i> . <i>Infection and Immunity</i> , 2006, 74, 1944-1948.	1.0	34
63	New Generation Vaccine Induces Effective Melanoma-Specific CD8+ T Cells in the Circulation but Not in the Tumor Site. <i>Journal of Immunology</i> , 2006, 177, 1670-1678.	0.4	157
64	CpG ODN As a Th1 Immune Enhancer for Prophylactic and Therapeutic Vaccines. , 2006, , 87-110.		5
65	Biodistribution and metabolism of immunostimulatory oligodeoxynucleotide CPG 7909 in mouse and rat tissues following subcutaneous administration. <i>Biochemical Pharmacology</i> , 2005, 69, 981-991.	2.0	30
66	CpG-DNA protects against a lethal orthopoxvirus infection in a murine model. <i>Antiviral Research</i> , 2005, 65, 87-95.	1.9	45
67	Stimulation via Toll-like receptor 9 reduces <i>Cryptococcus neoformans</i> -induced pulmonary inflammation in an IL-12-dependent manner. <i>European Journal of Immunology</i> , 2005, 35, 273-281.	1.6	51
68	Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. <i>Journal of Experimental Medicine</i> , 2005, 202, 1575-1585.	4.2	478
69	Deoxycytidyl-Deoxyguanosine Oligonucleotide Classes A, B, and C Induce Distinct Cytokine Gene Expression Patterns in Rhesus Monkey Peripheral Blood Mononuclear Cells and Distinct Alpha Interferon Responses in TLR9-Expressing Rhesus Monkey Plasmacytoid Dendritic Cells. <i>Vaccine Journal</i> , 2005, 12, 606-621.	3.2	51
70	Antibody Repertoire Development in Fetal and Neonatal Piglets. IX. Three Pathogen-Associated Molecular Patterns Act Synergistically to Allow Germfree Piglets to Respond to Type 2 Thymus-Independent and Thymus-Dependent Antigens. <i>Journal of Immunology</i> , 2005, 175, 6772-6785.	0.4	42
71	CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. <i>Aids</i> , 2005, 19, 1473-1479.	1.0	173
72	The Toll-Like Receptor 7 (TLR7) Agonist, Imiquimod, and the TLR9 Agonist, CpG ODN, Induce Antiviral Cytokines and Chemokines but Do Not Prevent Vaginal Transmission of Simian Immunodeficiency Virus When Applied Intravaginally to Rhesus Macaques. <i>Journal of Virology</i> , 2005, 79, 14355-14370.	1.5	126

#	ARTICLE	IF	CITATIONS
73	Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. <i>Journal of Clinical Investigation</i> , 2005, 115, 739-746.	3.9	569
74	CpG Oligodeoxynucleotides for Mucosal Vaccines. , 2005, , 959-965.		2
75	Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. <i>Clinical Cancer Research</i> , 2005, 11, 361-9.	3.2	109
76	Immunopharmacology of CpG Oligodeoxynucleotides and Ribavirin. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 2314-2317.	1.4	26
77	CpG Oligodeoxynucleotide Enhances Tumor Response to Radiation. <i>Cancer Research</i> , 2004, 64, 5074-5077.	0.4	145
78	Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity. <i>Journal of Leukocyte Biology</i> , 2004, 76, 585-593.	1.5	17
79	Malaria Blood Stage Parasites Activate Human Plasmacytoid Dendritic Cells and Murine Dendritic Cells through a Toll-Like Receptor 9-Dependent Pathway. <i>Journal of Immunology</i> , 2004, 172, 4926-4933.	0.4	245
80	CpG Oligodeoxynucleotides Stimulate Protective Innate Immunity against Pulmonary <i>Klebsiella</i> Infection. <i>Journal of Immunology</i> , 2004, 173, 5148-5155.	0.4	99
81	CpG oligodeoxynucleotides stimulate IFN- β -inducible protein-10 production in human B cells. <i>Journal of Endotoxin Research</i> , 2004, 10, 431-438.	2.5	48
82	Immunostimulatory CpG Oligodeoxynucleotide Confers Protection in a Murine Model of Infection with <i>Burkholderia pseudomallei</i> . <i>Infection and Immunity</i> , 2004, 72, 4494-4502.	1.0	56
83	Comparison of CpG s-ODNs, chromatin immune complexes, and dsDNA fragment immune complexes in the TLR9-dependent activation of rheumatoid factor B cells. <i>Journal of Endotoxin Research</i> , 2004, 10, 247-251.	2.5	36
84	CpG Oligodeoxynucleotide and Montanide ISA 51 Adjuvant Combination Enhanced the Protective Efficacy of a Subunit Malaria Vaccine. <i>Infection and Immunity</i> , 2004, 72, 949-957.	1.0	87
85	Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation. <i>Immunology</i> , 2004, 113, 212-223.	2.0	133
86	Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. <i>Current Oncology Reports</i> , 2004, 6, 88-95.	1.8	201
87	Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. <i>European Journal of Immunology</i> , 2004, 34, 251-262.	1.6	537
88	Modulation of CpG Oligodeoxynucleotide-Mediated Immune Stimulation by Locked Nucleic Acid (LNA) Oligonucleotides, 2004, 14, 23-31.	2.7	51
89	Human Plasmacytoid Dendritic Cells Activated by CpG Oligodeoxynucleotides Induce the Generation of CD4+CD25+ Regulatory T Cells. <i>Journal of Immunology</i> , 2004, 173, 4433-4442.	0.4	578
90	Induction of autoantibody production but not autoimmune disease in HEL transgenic mice vaccinated with HEL in combination with CpG or control oligodeoxynucleotides. <i>Vaccine</i> , 2004, 22, 2641-2650.	1.7	9

#	ARTICLE	IF	CITATIONS
91	C-Class CpG ODN: sequence requirements and characterization of immunostimulatory activities on mRNA level. <i>Immunobiology</i> , 2004, 209, 141-154.	0.8	66
92	Induction of Systemic TH1-Like Innate Immunity in Normal Volunteers Following Subcutaneous but Not Intravenous Administration of CPG 7909, a Synthetic B-Class CpG Oligodeoxynucleotide TLR9 Agonist. <i>Journal of Immunotherapy</i> , 2004, 27, 460-471.	1.2	178
93	Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotypic vaccine that mimics carcinoembryonic antigen. <i>Cancer Immunology, Immunotherapy</i> , 2003, 52, 317-327.	2.0	29
94	CpG motifs: the active ingredient in bacterial extracts?. <i>Nature Medicine</i> , 2003, 9, 831-835.	15.2	264
95	P-Chirality-Dependent Immune Activation by Phosphorothioate CpG Oligodeoxynucleotides. <i>Oligonucleotides</i> , 2003, 13, 491-499.	2.7	44
96	CpG DNA: Trigger of Sepsis, Mediator of Protection, or Both?. <i>Scandinavian Journal of Infectious Diseases</i> , 2003, 35, 653-659.	1.5	44
97	Convergence of CpG DNA- and BCR-mediated signals at the c-Jun N-terminal kinase and NF-kappaB activation pathways: regulation by mitogen-activated protein kinases. <i>International Immunology</i> , 2003, 15, 577-591.	1.8	53
98	Oral Pretreatment of Mice with CpG DNA Reduces Susceptibility to Oral or Intraperitoneal Challenge with Virulent <i>Listeria monocytogenes</i> . <i>Infection and Immunity</i> , 2003, 71, 4398-4404.	1.0	23
99	CpG-A-Induced Monocyte IFN- β -Inducible Protein-10 Production Is Regulated by Plasmacytoid Dendritic Cell-Derived IFN- α . <i>Journal of Immunology</i> , 2003, 170, 4061-4068.	0.4	78
100	Inhibitory Oligonucleotides Block the Induction of AP-1 Transcription Factor by Stimulatory CpG Oligonucleotides in B Cells. <i>Oligonucleotides</i> , 2003, 13, 143-150.	4.4	24
101	Synergy between CpG- or non-CpG DNA and specific antigen for B cell activation. <i>International Immunology</i> , 2003, 15, 223-231.	1.8	44
102	CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. <i>Cancer Research</i> , 2003, 63, 394-9.	0.4	86
103	CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. <i>Clinical Cancer Research</i> , 2003, 9, 3105-14.	3.2	109
104	Accumulation of Glutathione Disulfide Mediates NF- κ B Activation During Immune Stimulation with CpG DNA. <i>Oligonucleotides</i> , 2002, 12, 327-340.	4.4	15
105	Highly Immunostimulatory CpG-Free Oligodeoxynucleotides for Activation of Human Leukocytes. <i>Oligonucleotides</i> , 2002, 12, 165-175.	4.4	59
106	B Cells Express Ly-6C in a Th1 but Not Th2 Cytokine Environment. <i>Journal of Interferon and Cytokine Research</i> , 2002, 22, 799-806.	0.5	9
107	Role of Mitogen-Activated Protein Kinases in CpG DNA-Mediated IL-10 and IL-12 Production: Central Role of Extracellular Signal-Regulated Kinase in the Negative Feedback Loop of the CpG DNA-Mediated Th1 Response. <i>Journal of Immunology</i> , 2002, 168, 4711-4720.	0.4	190
108	Antitumor Mechanisms of Oligodeoxynucleotides with CpG and PolyG Motifs in Murine Prostate Cancer Cells: Decrease of NF- κ B and AP-1 Binding Activities and Induction of Apoptosis. <i>Oligonucleotides</i> , 2002, 12, 155-164.	4.4	17

#	ARTICLE	IF	CITATIONS
109	Comparative analysis of murine marrow-derived dendritic cells generated by Flt3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses. <i>Blood</i> , 2002, 100, 4169-4176.	0.6	69
110	CPG MOTIFS IN BACTERIAL DNA AND THEIR IMMUNE EFFECTS. <i>Annual Review of Immunology</i> , 2002, 20, 709-760.	9.5	2,342
111	Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells. <i>European Journal of Immunology</i> , 2002, 32, 1212.	1.6	138
112	A role for Toll in autoimmunity. <i>Nature Immunology</i> , 2002, 3, 423-424.	7.0	74
113	Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. <i>Nature Immunology</i> , 2002, 3, 499-499.	7.0	875
114	Bacterial DNA does not increase serum corticosterone concentration or prevent increases induced by other stimuli. <i>International Immunopharmacology</i> , 2001, 1, 1605-1614.	1.7	12
115	Now I know my CpGs. <i>Trends in Microbiology</i> , 2001, 9, 249-252.	3.5	75
116	Type I Interferon Is the Primary Regulator of Inducible Ly-6C Expression on T Cells. <i>Journal of Interferon and Cytokine Research</i> , 2001, 21, 621-629.	0.5	29
117	CpG Stimulation of Primary Mouse B Cells Is Blocked by Inhibitory Oligodeoxyribonucleotides at a Site Proximal to NF- κ B Activation. <i>Oligonucleotides</i> , 2001, 11, 247-256.	4.4	101
118	CpG Motif Identification for Veterinary and Laboratory Species Demonstrates That Sequence Recognition Is Highly Conserved. <i>Oligonucleotides</i> , 2001, 11, 333-340.	4.4	202
119	CpG Oligodeoxynucleotides. , 2001, 31, 229-232.		5
120	Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients. <i>Blood</i> , 2001, 98, 1217-1225.	0.6	79
121	Identification of CpG oligonucleotide sequences with high induction of IFN- γ in plasmacytoid dendritic cells. <i>European Journal of Immunology</i> , 2001, 31, 2154-2163.	1.6	790
122	Whole blood cultures to assess the immunostimulatory activities of CpG oligodeoxynucleotides. <i>Journal of Immunological Methods</i> , 2001, 247, 83-94.	0.6	34
123	Biodegradable microspheres containing group B <i>Streptococcus</i> vaccine: Immune response in mice. <i>American Journal of Obstetrics and Gynecology</i> , 2001, 185, 1174-1179.	0.7	41
124	Divergent Therapeutic and Immunologic Effects of Oligodeoxynucleotides with Distinct CpG Motifs. <i>Journal of Immunology</i> , 2001, 167, 4878-4886.	0.4	221
125	Interleukin-12- and Gamma Interferon-Dependent Protection against Malaria Conferred by CpG Oligodeoxynucleotide in Mice. <i>Infection and Immunity</i> , 2001, 69, 1643-1649.	1.0	144
126	Lactoferrin Binds CpG-Containing Oligonucleotides and Inhibits Their Immunostimulatory Effects on Human B Cells. <i>Journal of Immunology</i> , 2001, 167, 2921-2928.	0.4	87

#	ARTICLE	IF	CITATIONS
127	CpG DNA induces cyclooxygenase-2 expression and prostaglandin production. <i>International Immunology</i> , 2001, 13, 1013-1020.	1.8	37
128	Lipopolysaccharide and CpG DNA synergize for tumor necrosis factor- α production through activation of NF- κ B. <i>International Immunology</i> , 2001, 13, 1391-1404.	1.8	73
129	From Bugs to Drugs: Therapeutic Immunomodulation with Oligodeoxynucleotides Containing CpG Sequences from Bacterial DNA. <i>Oligonucleotides</i> , 2001, 11, 181-188.	4.4	56
130	Identification of CpG oligonucleotide sequences with high induction of IFN- α / β in plasmacytoid dendritic cells. , 2001, 31, 2154.		3
131	Signal transduction induced by immunostimulatory CpG DNA. , 2001, , 97-105.		0
132	Rescue of B cells from apoptosis by immune stimulatory CpG DNA. , 2001, , 55-61.		0
133	The role of CpG motifs in innate immunity. <i>Current Opinion in Immunology</i> , 2000, 12, 35-43.	2.4	321
134	Immune effects and therapeutic applications of CpG motifs in bacterial DNA. <i>Immunopharmacology</i> , 2000, 48, 303-305.	2.0	23
135	Causing a commotion in the blood: immunotherapy progresses from bacteria to bacterial DNA. <i>Trends in Immunology</i> , 2000, 21, 521-526.	7.5	117
136	Rescue of B cells from apoptosis by immune stimulatory CpG DNA. <i>Seminars in Immunopathology</i> , 2000, 22, 55-61.	4.0	13
137	Delineation of a CpG Phosphorothioate Oligodeoxynucleotide for Activating Primate Immune Responses In Vitro and In Vivo. <i>Journal of Immunology</i> , 2000, 164, 1617-1624.	0.4	550
138	APC Stimulated by CpG Oligodeoxynucleotide Enhance Activation of MHC Class I-Restricted T Cells. <i>Journal of Immunology</i> , 2000, 165, 6244-6251.	0.4	77
139	CpG DNA Induces Maturation of Dendritic Cells with Distinct Effects on Nascent and Recycling MHC-II Antigen-Processing Mechanisms. <i>Journal of Immunology</i> , 2000, 165, 6889-6895.	0.4	117
140	Minding the Cs and Gs. <i>Molecular Therapy</i> , 2000, 1, 209-210.	3.7	15
141	Enhanced Dendritic Cell Maturation by TNF- α or Cytidine-Phosphate-Guanosine DNA Drives T Cell Activation In Vitro and Therapeutic Anti-Tumor Immune Responses In Vivo. <i>Journal of Immunology</i> , 2000, 165, 6278-6286.	0.4	167
142	CpG DNA is an effective oral adjuvant to protein antigens in mice. <i>Vaccine</i> , 2000, 19, 950-957.	1.7	99
143	Immune effects and mechanisms of action of CpG motifs. <i>Vaccine</i> , 2000, 19, 618-622.	1.7	148
144	CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. <i>Vaccine</i> , 2000, 18, 1920-1924.	1.7	164

#	ARTICLE	IF	CITATIONS
145	Mechanism and Function of a Newly Identified CpG DNA Motif in Human Primary B Cells. <i>Journal of Immunology</i> , 2000, 164, 944-953.	0.4	567
146	Signal transduction induced by immunostimulatory CpG DNA. <i>Seminars in Immunopathology</i> , 2000, 22, 97-106.	4.0	13
147	CpG DNA rescues B cells from apoptosis by activating NF κ B and preventing mitochondrial membrane potential disruption via a chloroquine-sensitive pathway. <i>International Immunology</i> , 1999, 11, 2015-2024.	1.8	81
148	Bacterial DNA and CpG-Containing Oligodeoxynucleotides Activate Cutaneous Dendritic Cells and Induce IL-12 Production: Implications for the Augmentation of Th1 Responses. <i>International Archives of Allergy and Immunology</i> , 1999, 118, 457-461.	0.9	79
149	Phagocytic antigen processing and effects of microbial products on antigen processing and T-cell responses. <i>Immunological Reviews</i> , 1999, 168, 217-239.	2.8	47
150	Mechanisms and therapeutic applications of immune stimulatory CpG DNA. , 1999, 84, 113-120.		70
151	Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1999, 1489, 107-116.	2.4	133
152	Direct Immunologic activities of CpG DNA and implications for gene therapy. <i>Journal of Gene Medicine</i> , 1999, 1, 56-63.	1.4	10
153	A possible cause of joint destruction in septic arthritis. <i>Arthritis Research</i> , 1999, 1, 3.	2.0	15
154	CpG DNA: a novel immunomodulator. <i>Trends in Microbiology</i> , 1999, 7, 64-65.	3.5	42
155	Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. <i>Vaccine</i> , 1999, 17, 3065-3071.	1.7	144
156	CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma. <i>Journal of Allergy and Clinical Immunology</i> , 1999, 104, 1258-1264.	1.5	132
157	Direct Immunologic activities of CpG DNA and implications for gene therapy. <i>Journal of Gene Medicine</i> , 1999, 1, 56-63.	1.4	106
158	How to Exclude Immunostimulatory and Other Nonantisense Effects of Antisense Oligonucleotides. <i>Perspectives in Antisense Science</i> , 1999, , 79-89.	0.2	1
159	Immune Effects of Bacterial DNA and Their Possible Role in the Pathogenesis of Lupus. , 1999, , 79-100.		2
160	CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. <i>Vaccine</i> , 1998, 16, 1216-1224.	1.7	279
161	The role of CpG dinucleotides in DNA vaccines. <i>Trends in Microbiology</i> , 1998, 6, 23-27.	3.5	229
162	The CpG Motif. <i>BioDrugs</i> , 1998, 10, 341-346.	2.2	17

#	ARTICLE	IF	CITATIONS
163	Reduction of Antigen Expression from DNA Vaccines by Coadministered Oligodeoxynucleotides. <i>Oligonucleotides</i> , 1998, 8, 351-356.	4.4	81
164	Immunostimulatory CpG Oligodeoxynucleotides Enhance the Immune Response to Vaccine Strategies Involving Granulocyte-Macrophage Colony-Stimulating Factor. <i>Blood</i> , 1998, 92, 3730-3736.	0.6	119
165	Immunostimulatory CpG Oligodeoxynucleotides Enhance the Immune Response to Vaccine Strategies Involving Granulocyte-Macrophage Colony-Stimulating Factor. <i>Blood</i> , 1998, 92, 3730-3736.	0.6	3
166	Interleukin-10 Functions <i>In Vitro</i> and <i>In Vivo</i> to Inhibit Bacterial DNA-Induced Secretion of Interleukin-12. <i>Journal of Interferon and Cytokine Research</i> , 1997, 17, 781-788.	0.5	45
167	Identification of an Oligodeoxynucleotide Sequence Motif That Specifically Inhibits Phosphorylation by Protein Tyrosine Kinases. <i>Oligonucleotides</i> , 1997, 7, 115-123.	4.4	13
168	CpG Oligodeoxynucleotides Act as Adjuvants that Switch on T Helper 1 (Th1) Immunity. <i>Journal of Experimental Medicine</i> , 1997, 186, 1623-1631.	4.2	953
169	Immunostimulatory Oligodeoxynucleotides Containing CpG Motifs Enhance the Efficacy of Monoclonal Antibody Therapy of Lymphoma. <i>Blood</i> , 1997, 89, 2994-2998.	0.6	184
170	Bacterial DNA-Induced NK Cell IFN- γ Production Is Dependent on Macrophage Secretion of IL-12. <i>Clinical Immunology and Immunopathology</i> , 1997, 84, 185-193.	2.1	259
171	Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. <i>Trends in Microbiology</i> , 1996, 4, 73-77.	3.5	122
172	An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA. <i>Translational Research</i> , 1996, 128, 128-133.	2.4	113
173	Oligodeoxynucleotide Modifications Determine the Magnitude of B Cell Stimulation by CpG Motifs. <i>Oligonucleotides</i> , 1996, 6, 133-139.	4.4	81
174	Phosphorothioate Oligodeoxynucleotides: Antisense or Anti-Protein?. <i>Antisense Research and Development</i> , 1995, 5, 241-241.	3.3	112
175	CpG DNA: A pathogenic factor in systemic lupus erythematosus?. <i>Journal of Clinical Immunology</i> , 1995, 15, 284-292.	2.0	155
176	CpG motifs in bacterial DNA trigger direct B-cell activation. <i>Nature</i> , 1995, 374, 546-549.	13.7	3,329
177	Interruption of a transforming growth factor β autocrine loop in Caco-2 cells by antisense oligodeoxynucleotides. <i>Gastroenterology</i> , 1995, 109, 1882-1889.	0.6	11
178	Potential of Antisense Technology in the Treatment of Immunological Disorders. <i>BioDrugs</i> , 1995, 4, 169-179.	0.7	3
179	Retroviruses and Their Roles in Chronic Inflammatory Diseases and Autoimmunity. , 1995, , 491-603.		19
180	Oligonucleotides with novel, cationic backbone substituents: aminoethylphosphonates. <i>Nucleic Acids Research</i> , 1994, 22, 5416-5424.	6.5	49

#	ARTICLE	IF	CITATIONS
181	Role of Endogenous Retroviruses in Autoimmune Diseases.. Tohoku Journal of Experimental Medicine, 1994, 173, 105-114.	0.5	5
182	Inhibition of T4 Polynucleotide Kinase Activity by Phosphorothioate and Chimeric Oligodeoxynucleotides. Antisense Research and Development, 1994, 4, 295-297.	3.3	16
183	Administration of a Phosphorothioate Oligonucleotide Antisense to Murine Endogenous Retroviral MCF env Causes Immune Effects in Vivo in a Sequence-Specific Manner. Clinical Immunology and Immunopathology, 1993, 67, 130-136.	2.1	36
184	Comparison of Cellular Binding and Uptake of Antisense Phosphodiester, Phosphorothioate, and Mixed Phosphorothioate and Methylphosphonate Oligonucleotides. Antisense Research and Development, 1993, 3, 53-66.	3.3	224
185	Nonspecific Suppression of [3H]Thymidine Incorporation by "Control" Oligonucleotides. Antisense Research and Development, 1992, 2, 325-330.	3.3	32
186	Heterogeneous Expression and Coordinate Regulation of Endogenous Retroviral Sequences in Human Peripheral Blood Mononuclear Cells. AIDS Research and Human Retroviruses, 1992, 8, 1991-1998.	0.5	44
187	Molecular Aspects of Systemic Lupus Erythematosus: Murine Endogenous Retroviral Expression. DNA and Cell Biology, 1992, 11, 253-257.	0.9	6
188	Applications of antisense oligodeoxynucleotides in immunology and autoimmunity research. ImmunoMethods, 1992, 1, 191-202.	0.8	12
189	Endogenous retroviruses: potential etiologic agents in autoimmunity. FASEB Journal, 1992, 6, 2537-2544.	0.2	142
190	Uptake of Oligodeoxyribonucleotides by Lymphoid Cells Is Heterogeneous and Inducible. Antisense Research and Development, 1991, 1, 161-171.	3.3	95
191	Theoretical and Experimental Approaches to Generalized Autoimmunity. Immunological Reviews, 1990, 118, 129-163.	2.8	78
192	Retroviruses and autoimmunity. Journal of Autoimmunity, 1990, 3, 137-166.	3.0	106
193	Expression of an endogenous retroviral transcript is associated with murine lupus. Arthritis and Rheumatism, 1989, 32, 322-329.	6.7	22
194	Increased expression of novel full-length endogenous mink cell focus-forming-related transcripts in autoimmune mouse strains. Virology, 1988, 162, 274-276.	1.1	25
195	Immunostimulatory Potential of Silencing RNAs Can Be Mediated by a Non-Uridine-Rich Toll-Like Receptor 7 Motif. Oligonucleotides, 0, , 121102072334007.	2.7	0